Gamma Medica, a molecular breast imaging (MBI) technology company, reached an agreement with Hospital Services Limited (HSL), a medical device company that distributes, installs and services radiology capital equipment and medical devices.
Women with breast dense tissue between the ages of 50 and 79 years old and in the United Kingdom and Ireland will now have access to Gamma Medica’s LumaGEM MBI system, that improves early detection of breast cancer. This technology has also proven to be as effective as a secondary screening method compared to ultrasound or MRI with far fewer false positives.
“We are pleased that through our collaboration with HSL, women with dense breasts in the UK, Ireland and the Channel Islands, will soon have access to the LumaGEM MBI technology,” said Philip Croxford, Gamma Medica President and CEO in a statement. “This partnership is the first step in Gamma Medica’s global expansion to increase awareness and access to clinical superior breast imaging technology worldwide. Leveraging HSL’s network enables Gamma Medica to continue to promote early detection on an international scale.”
A study published in the American Journal of Roentgenology found that after monitoring 1,700 women with dense breast tissue over a three-year period, the LumaGEM’s cancer detection rate was 7.7 cancers per 1,000, an increase from three cancers per 1,000 with mammography alone. The additional breast cancers also accounted for about 85 percent of those being invasive and node negative, indicating they were detected at an early stage and improved a patient's likelihood of a better prognosis.
“Introducing Gamma Medica to the European market will enable women outside of the United States to receive the early detection technology they need,” said Dominic Walsh, CEO of Hospital Services Limited in a press release. "We’re excited to be Gamma Medica’s partner in this endeavor.”